Alphatec (NSDQ:ATEC) said last week that it succeeded in raising $57.7 million in a stock offering for its line of spine implants. The Carlsbad, Calif.-based company had said it planned to float 10.9 million shares at $4.60 apiece, for gross proceeds of $50.1 million. That number rose to $57.7 million because the flotation’s underwriters fully […]
Piper Jaffray
Medtech panel says environment for IPOs remains strong
With 2014 a rebounding year for medical device and biopharmaceutical IPOs, 2015 should build further on that progress, a panel at the MedTech Investing Conference said this week.
HealthQuest Capital looks to investments with its new $110M funding round | Medtech funding for the week of August 18, 2014
Will Medtronic abandon inversion in Covidien deal? | Medtech Wall Street news for the week of August 18, 2014
ElectroCore seeks commercial partners for non-invasive headache tech
ElectroCore said it tapped investment bank Piper Jaffray to help it court potential partners to commercialize the non-invasive vagus nerve stimulation treatment for headaches it’s developing.
Biolase adds 2 to board, taps Piper Jaffray for advice on ‘strategic alternatives’
Solta Medical gains on swing to Q3 black, layoffs, possible acquisition
Solta Medical (NSDQ:SLTM) shares gained today after the medical device company reported a swing to 3rd-quarter black ink and said it’s considering a sale.
Abiomed rebounds after 4% slide on Piper Jaffray downgrade | Wall Street Beat
Abiomed (NSDQ:ABMD) shares clawed back some of the nearly 4% lost yesterday as investors reacted to a downgrade by analysts at Piper Jaffray.
The Danvers, Mass.-based medical device company’s stock fell from a $17.20-per-share close April 8 to end yesterday at $16.52 per share, a more than 3.9% decline. ABMD shares were trading at $16.98 apiece as of about 11 this morning, however, up 2.8%.
Analysts bearish on C.R. Bard
Analysts at a trio of investment advisory firms downgraded their estimates for C.R. Bard (NYSE:BCR) stock, which hasn’t fared well recently.
